Serum preadipocyte factor 1 concentrations and risk of developing diabetes: a nested case-control study

Area of Science:

• Metabolic disease research
• Biomarker discovery
• Diabetes epidemiology

Background:

• Diabetes mellitus is a growing global health concern.
• Identifying reliable predictive markers for diabetes is crucial for early intervention.
• Preadipocyte factor 1 (PAf1) is a protein with potential roles in metabolic regulation.

Purpose of the Study:

• To investigate whether circulating preadipocyte factor 1 levels can serve as a predictive marker for the development of type 2 diabetes.
• To assess the association between baseline preadipocyte factor 1 levels and future glucose intolerance in a population-based cohort.

Main Methods:

• A nested case-control study design was employed using data from the Chungju Metabolic disease Cohort Study.
• Participants who developed diabetes or prediabetes over a 4-year follow-up were compared to controls with normal glucose tolerance.
• Circulating preadipocyte factor 1 levels were quantified using enzyme-linked immunosorbent assay (ELISA).

Main Results:

• Baseline preadipocyte factor 1 levels demonstrated a significant stepwise decrease across normal glucose tolerance, prediabetes, and diabetes groups (P for trend = 0.0151).
• Lower preadipocyte factor 1 levels were observed in individuals with increased fasting plasma glucose or decreased beta-cell function at follow-up.
• After multivariable adjustment, individuals in the lowest quartile of preadipocyte factor 1 had a nearly threefold higher risk of developing diabetes (RR 2.794), a finding significant in women.

Conclusions:

• Circulating preadipocyte factor 1 may function as a valuable biomarker for predicting diabetes development.
• The predictive utility of preadipocyte factor 1 appears particularly pronounced in women.
• Further research is warranted to elucidate the precise mechanisms underlying the association between preadipocyte factor 1 and diabetes risk.